Use of monoclonal antibody therapy for nosocomial SARS-CoV-2 infection in patients at high risk for severe COVID-19: experience from a tertiary-care hospital in Germany.
Bamlanivimab
COVID-19
Casirivimab
Imdevimab
Monoclonal spike antibodies
SARS-CoV2
Journal
Infection
ISSN: 1439-0973
Titre abrégé: Infection
Pays: Germany
ID NLM: 0365307
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
23
04
2021
accepted:
30
06
2021
pubmed:
11
7
2021
medline:
27
11
2021
entrez:
10
7
2021
Statut:
ppublish
Résumé
Additional treatment options for coronavirus disease (COVID-19) are urgently needed, particularly for populations at high risk of severe disease. This cross-sectional, retrospective study characterized the outcomes of 43 patients with nosocomial severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection with and without treatment using monoclonal SARS-CoV-2 spike antibodies (bamlanivimab or casirivimab/imdevimab). Our results indicate that treatment with monoclonal antibodies results in a significant decrease in disease progression and mortality when used for asymptomatic patients with early SARS-CoV-2 infection.
Identifiants
pubmed: 34244967
doi: 10.1007/s15010-021-01657-y
pii: 10.1007/s15010-021-01657-y
pmc: PMC8269399
doi:
Substances chimiques
Antibodies, Monoclonal
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1313-1318Informations de copyright
© 2021. The Author(s).
Références
RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384:693–704.
doi: 10.1056/NEJMoa2021436
Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, et al. Remdesivir for the treatment of Covid-19—final report. N Engl J Med. 2020;383:1813–26.
doi: 10.1056/NEJMoa2007764
Chen P, Nirula A, Heller B, Gottlieb RL, Boscia J, Morris J, Huhn G, Cardona J, Mocherla B, Stosor V, et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. N Engl J Med. 2021;384:229–37.
doi: 10.1056/NEJMoa2029849
ACTIV-3/TICO LY-CoV555 Study Group, Lundgren JD, Grund B, Barkauskas CE, Holland TL, Gottlieb RL, Sandkovsky U, Brown SM, Knowlton KU, Self WH, et al. A neutralizing monoclonal antibody for hospitalized patients with Covid-19. N Engl J Med. 2021;384:905–14.
doi: 10.1056/NEJMoa2033130
Starr TN, Greaney AJ, Addetia A, Hannon WW, Choudhary MC, Dingens AS, Li JZ, Bloom JD. Prospective mapping of viral mutations that escape antibodies used to treat COVID-19. Science. 2021;371:850–4.
doi: 10.1126/science.abf9302
Hoffmann M, Arora P, Gross R, Seidel A, Hornich BF, Hahn AS, Kruger N, Graichen L, Hofmann-Winkler H, Kempf A, et al. SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. Cell. 2021;184:2384-2393.e12.
doi: 10.1016/j.cell.2021.03.036
Booth A, Reed AB, Ponzo S, Yassaee A, Aral M, Plans D, Labrique A, Mohan D. Population risk factors for severe disease and mortality in COVID-19: a global systematic review and meta-analysis. PLoS ONE. 2021;16: e0247461.
doi: 10.1371/journal.pone.0247461
Kumar RN, Wu EL, Stosor V, Moore WJ, Achenbach C, Ison MG, Angarone MP. Real-world experience of bamlanivimab for COVID-19: a case-control study. Clin Infect Dis. 2021. https://doi.org/10.1093/cid/ciab305 .
doi: 10.1093/cid/ciab305
pubmed: 34791136